B-Cell CLL-Lymphoma 10 Protein
"B-Cell CLL-Lymphoma 10 Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A signal transducing adaptor protein that contains an N-terminal CARD DOMAIN and functions in the ADAPTIVE IMMUNE RESPONSE. It promotes PRO-CASPASE-9 maturation and APOPTOSIS, activation of NF-KAPPA B, and is a substrate for MALT1 PARACASPASE.
| Descriptor ID |
D000074018
|
| MeSH Number(s) |
D12.644.360.024.131.140 D12.644.360.075.358.140 D12.776.157.057.006.140 D12.776.476.024.139.140 D12.776.476.075.358.140
|
| Concept/Terms |
B-Cell CLL-Lymphoma 10 Protein- B-Cell CLL-Lymphoma 10 Protein
- B Cell CLL Lymphoma 10 Protein
- Bcl-10 Protein
- Bcl 10 Protein
- B-Cell Lymphoma-Leukemia 10 Protein
- B Cell Lymphoma Leukemia 10 Protein
- Bcl10 Protein
|
Below are MeSH descriptors whose meaning is more general than "B-Cell CLL-Lymphoma 10 Protein".
Below are MeSH descriptors whose meaning is more specific than "B-Cell CLL-Lymphoma 10 Protein".
This graph shows the total number of publications written about "B-Cell CLL-Lymphoma 10 Protein" by people in this website by year, and whether "B-Cell CLL-Lymphoma 10 Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 3 | 3 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 5 | 5 |
| 2003 | 0 | 9 | 9 |
| 2004 | 0 | 11 | 11 |
| 2005 | 0 | 8 | 8 |
| 2006 | 0 | 14 | 14 |
| 2007 | 0 | 12 | 12 |
| 2008 | 0 | 14 | 14 |
| 2009 | 0 | 7 | 7 |
| 2010 | 0 | 6 | 6 |
| 2011 | 0 | 4 | 4 |
| 2012 | 0 | 7 | 7 |
| 2013 | 0 | 5 | 5 |
| 2014 | 0 | 14 | 14 |
| 2015 | 0 | 3 | 3 |
| 2016 | 0 | 3 | 3 |
| 2017 | 4 | 3 | 7 |
| 2018 | 4 | 2 | 6 |
| 2019 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "B-Cell CLL-Lymphoma 10 Protein" by people in Profiles.
-
Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy. Nature. 2019 06; 570(7759):112-116.
-
Germline CBM-opathies: From immunodeficiency to atopy. J Allergy Clin Immunol. 2019 05; 143(5):1661-1673.
-
Double-strand break repair through homologous recombination in autosomal-recessive BCL10 deficiency. J Allergy Clin Immunol. 2019 05; 143(5):1931-1934.e1.
-
Cellular metabolism constrains innate immune responses in early human ontogeny. Nat Commun. 2018 11 16; 9(1):4822.
-
A CARD9 Founder Mutation Disrupts NF-?B Signaling by Inhibiting BCL10 and MALT1 Recruitment and Signalosome Formation. Front Immunol. 2018; 9:2366.
-
Molecular architecture and regulation of BCL10-MALT1 filaments. Nat Commun. 2018 10 02; 9(1):4041.
-
The CBM-opathies-A Rapidly Expanding Spectrum of Human Inborn Errors of Immunity Caused by Mutations in the CARD11-BCL10-MALT1 Complex. Front Immunol. 2018; 9:2078.
-
Targeted deep sequencing of gastric marginal zone lymphoma identified alterations of TRAF3 and TNFAIP3 that were mutually exclusive for MALT1 rearrangement. Mod Pathol. 2018 09; 31(9):1418-1428.
-
Assembly mechanism of the CARMA1-BCL10-MALT1-TRAF6 signalosome. Proc Natl Acad Sci U S A. 2018 02 13; 115(7):1499-1504.
-
The CARMA3-Bcl10-MALT1 Signalosome Drives NF?B Activation and Promotes Aggressiveness in Angiotensin II Receptor-Positive Breast Cancer. Cancer Res. 2018 03 01; 78(5):1225-1240.